State Street
CADL icon

State Street’s Candel Therapeutics CADL Stock Holding History

State Street’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Buy
818,558
+26,340
+3% +$143K ﹤0.01% 3048
2025
Q4 		$4.48M Buy
792,218
+103,452
+15% +$557K ﹤0.01% 3041
2025
Q3 		$3.51M Buy
688,766
+36,787
+6% +$213K ﹤0.01% 3137
2025
Q2 		$3.3M Buy
651,979
+88,575
+16% +$456K ﹤0.01% 3117
2025
Q1 		$3.18M Buy
563,404
+2,435
+0.4% +$19.9K ﹤0.01% 3062
2024
Q4 		$4.87M Buy
560,969
+68,964
+14% +$407K ﹤0.01% 2995
2024
Q3 		$3.41M Buy
492,005
+19,207
+4% +$119K ﹤0.01% 3127
2024
Q2 		$2.93M Buy
472,798
+445,198
+1,613% +$3.34M ﹤0.01% 3157
2024
Q1 		$43.6K Hold
27,600
– – ﹤0.01% 4185
2023
Q4 		$40.6K Hold
27,600
– – ﹤0.01% 4229
2023
Q3 		$25.7K Hold
27,600
– – ﹤0.01% 4416
2023
Q2 		$34.8K Hold
27,600
– – ﹤0.01% 4508
2023
Q1 		$37.8K Hold
27,600
– – ﹤0.01% 4573
2022
Q4 		$49.4K Hold
27,600
– – ﹤0.01% 4560
2022
Q3 		$87K Hold
27,600
– – ﹤0.01% 4509
2022
Q2 		$89K Hold
27,600
– – ﹤0.01% 4569
2022
Q1 		$140K Buy
27,600
+1,000
+4% +$4.96K ﹤0.01% 4518
2021
Q4 		$208K Hold
26,600
– – ﹤0.01% 4332
2021
Q3 		$288K Buy
+26,600
New +$221K ﹤0.01% 4217

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's CADL Position: Q1 2026 in Review

State Street increased its Candel Therapeutics (CADL) stake by 3.3% in Q1 2026, buying an estimated $143K and bringing the position to 818,558 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3048.

State Street first reported a position in CADL in Q3 2021 and has held it in 19 quarters since. The position peaked at $4.87M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • State Street held 818,558 shares of Candel Therapeutics worth $4.01M as of Q1 2026.
  • State Street bought 26,340 Candel Therapeutics shares in Q1 2026, an estimated $143K.
  • Candel Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3048 holding.
  • State Street first reported a position in Candel Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • State Street's Candel Therapeutics position peaked at $4.87M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.